Clinical trials: Patients With Prostate Cancer
- Condition Patients With Prostate Cancer
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Prostate Cancer
Study of ATN-224 in Patients With Prostate Cancer
This is a multicenter, randomized, phase II study of the safety and efficacy of two dose levels of oral ATN-224 in patients with prostate cancer with a rising serum PSA in the absence of detectable disease.
- Trial name
- NCT00405574
- Testing
- ATN-224
- Where
- 6 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Attenuon
Prostate Cancer, mCRPC
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
This clinical trial is an open-label, single-arm, multi-center, escalation (Phase 1 Part B only), rater-blind (Phase 2 only), phase 1/2 trial to evaluate the diagnostic validity/safety of Ga-68-NGUL and efficacy/safety of…
- Trial name
- NCT05547061
- Testing
- Lu-177-DGUL, Ga-68-NGUL
- Where
- 4 sites in South Korea
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Cellbion Co., Ltd.
Prostate Cancer
Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations for Radiation Oncologists
This clinical utility study is based on a review of real but de-identified and randomized patient cases and aims to evaluate radiation oncologist's treatment recommendations before and after reviewing the results provided by the…
- Trial name
- DECIDE3 (NCT02034812)
- Testing
- Decipher Questionnaire
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GenomeDx Biosciences Corp
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body
This study will be an open-label, fixed sequence study in healthy subjects (vasectomized males and females of non-childbearing potential), performed at a single study centre.
- Trial name
- NCT04712396
- Testing
- Capivasertib, Itraconazole
- Where
- Germany
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Prostate Cancer
Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations
This clinical utility study pilot is based on a review of real but de-identified and randomized patient cases and aims to evaluate Urologists' treatment recommendations before and after reviewing the results provided by the…
- Trial name
- DECIDE (NCT02020876)
- Testing
- DECIPHER Questionnaire
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GenomeDx Biosciences Corp
Healthy Adult, Prostate Cancer
The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer
This goal of this study is to investigate the dosimetry, safety, biodistribution of ⁶⁸Ga-FC516. In this study, we will evaluate the safety, biodistribution and dosimetry of ⁶⁸Ga-FC516 in subjects and compared them with the…
- Trial name
- NCT07468708
- Testing
- ⁶⁸Ga-FC516, ⁶⁸Ga-FC516 and ⁶⁸Ga-labeled prostate cancer-targeting tracer
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Diagnostic Imaging
PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers
PET/CT imaging study for evaluation of safety and tolerability and diagnostic performance of BAY1075553 in patients with prostate cancer and in healthy volunteers
- Trial name
- NCT01287845
- Testing
- BAY1075553
- Where
- 2 sites in United States, Austria
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.